semaglutide shortage fda Ozempic and Wegovy officially moved off FDA's drug list FDA Proposes Ban on Bulk
Description
10.1136/bmj.d4169 183
Membership required for purchase

Systematic reviews and comparative analyses suggest the following pattern: Dualagonists such as tirzepatide typically produce more weight loss than GLP1 singleagonists

Moreover, when patients discontinue these drugs, the weight that they regain is predominantly fat rather than muscle

Generic Ozempic is set to emerge in major markets from India and Brazil to China and Canada this year, reshaping the sector in those countries
